Lexaria Bioscience Corp. LXRP Archives - Page 23 of 27

TuesdayDec 26, 2017 1:44 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Set to Exploit the Cannabis Industry Utilizing Proprietary Technology

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is well positioned in the booming cannabis industry with its patent-protected technology, DehyraTECH™, which enables a more efficient delivery and absorption of cannabinoids. An article discussing this reads: “Lexaria research and development partnership with the Canadian government’s National Research Council underscores the significance of its unique technology. Results from the endeavor are expected to support accelerating B2B relationships – and not just in the booming cannabis and CBD/hemp oil industry. Much more can be done to enhance and enable delivery of active pharmaceutical ingredients in a wide variety of important health-related fields, offering Lexaria…

FridayDec 22, 2017 11:26 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) and its Revolutionary Technology are Ready for the Cannabis Industry

Worldwide cannabis market expected to reach between $30 billion and $50 billion within four years Patent protected disruptive technology enables more efficient delivery and absorption of cannabinoids Groundbreaking delivery technology DehyraTECH™ positions Lexaria as potential M&A prospect Lexaria BioScience Corp. (CSE: LXX) (OTCQB: LXRP), a Canadian biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, including cannabinoids, now has multiple patents pending in over 40 countries around the world. The company’s first patents, issued in the United States and Australia, relate to edible forms of cannabinoids or CBDs. Hot off a winning presentation at the 2017…

FridayDec 15, 2017 10:25 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Launches New Research Programs

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said it is engaging in a new topical skin cream research and development ("R&D") program; R&D regarding nicotine edibles; and provided an update on existing R&D programs. The company has developed topical cream products for the delivery of cannabinoids as an addition to its DehydraTECH™ technology. Laboratory testing for human skin absorption and penetration characteristics are scheduled for early 2018 for various formulations. Following its recent nicotine patent grant, Lexaria is advancing its research focus on edible forms of nicotine that could utilize the company’s DehydraTECH™ technology. Additionally, Lexaria plans to…

WednesdayDec 13, 2017 12:43 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Granted U.S. Patent Regarding DehydraTECH™ Technology

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) reported this morning that it has been granted a patent from the United States Patent and Trademark Office ("USPTO") increasing its intellectual property (“IP”) hold of its DehydraTECH™ technology. The newly-issued patent covers the use of DehydraTECH™ technology as a delivery platform for a broad range of Active Pharmaceutical Ingredients ("APIs") including all cannabinoids, fat soluble vitamins, non-steroidal anti-inflammatory pain medications ("NSAIDs"), and nicotine. In addition, Lexaria continues to advance all of its other patent applications worldwide. “This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be…

MondayDec 11, 2017 4:02 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Sets its Sights on Booming Global Cannabis Industry

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) patented delivery technology, DehydraTECH™ has positioned the company at the forefront of the thriving global cannabis industry. A recent article discussing this reads: “LXRP’s technology enables improved delivery of bioactive substances via oral ingestion that results in increased absorption without the need for unhealthy practices of inhalational dosing that result in damaging affects to the lungs. The technology also eliminates the need for co-administration with unhealthy sugars or sweeteners in delivery that are commonly used to mask the bitter tastes. With DehydraTECH™, bioactive substance delivery is improved by combining molecules with certain fatty acids…

FridayDec 08, 2017 2:23 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTech™ Shines in Vegas Lights

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) attracted a lot of attention in Las Vegas at this year’s Marijuana Business Conference & Expo due to increased awareness about potential health benefits of cannabinoids and an increased demand for improved CBD-based edibles. A recent article highlights keen interest in Lexaria’s patented DehydraTECH™ delivery technology, stating, “Lexaria’s proprietary technology has been awarded patents in the U.S. and Australia, and it has patents pending in more than 40 other countries. Furthermore, it is the only company in the world to date that has a patent allowed for the oral delivery of all non-psychoactive cannabinoids,…

FridayDec 08, 2017 12:00 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Partners with Stakeholders to Participate on Global Scale with DehydraTECH™

Amidst increasing awareness regarding potential health benefits of cannabinoids, Lexaria is at the forefront of a booming industry LXRP stakeholders have the opportunity to participate on a global scale to improve the delivery and performance of various products Lexaria’s patented technology provides an enabling layer in cannabinoid research and development, existing products and applications Amidst increasing awareness regarding cannabinoids and their potential health benefits, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is at the forefront of the booming cannabis industry with its patented delivery technology, DehydraTECH™. The technology provides an enabling layer to advances in cannabinoid research and development as…

MondayDec 04, 2017 10:21 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Wins in Vegas!

Major interest generated in Lexaria’s technology at MJBizCon Patented technology masks bitter taste of edibles, increases bio-absorption and reduces time to effect Lexaria’s proprietary tech enables lowest manufacturing cost per serving and best consumer experience This year’s three-day Marijuana Business Conference & Expo (MJBizCon) was held in Las Vegas in mid-November, with an attendance of over 18,000 people. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) had a full team at its exhibit, which attracted a lot of attention. The company noticed increased awareness and knowledge among conference-goers about cannabinoids and their potential health benefits. There was also a noticeable demand…

FridayDec 01, 2017 11:43 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Stock, Option and Warrant Transactions

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced various stock, option and warrant transactions. The news release states, “Following issuance of these common shares, Lexaria will have 69,674,919 common shares issued and outstanding. No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.” No shares were sold or registered in the United States. In addition, John Docherty, President of Lexaria Bioscience Corp., recently issued a clip discussing the company's technology…

WednesdayNov 29, 2017 9:00 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Technology Offers a Sweet Escape for Cannabis Users without Smoking or Sweeteners

Proprietary lipophilic enhancement technology boosts bioavailability of orally ingested cannabinoids and masks unpleasant taste Only company in the world to obtain a patent for improved oral or ingestible delivery of all cannabinoids, including both non-psychoactive and psychoactive Company generates revenue from out-licensing its technology The cannabis market is exploding globally as well as domestically, and Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has pioneered an enabling technology that enhances the body’s absorption of cannabinoids—an advancement from which many cannabis-related companies can profit. Lexaria’s proprietary lipophilic enhancement technology has demonstrated the ability to boost the bioavailability of all orally ingested cannabinoids.…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP